Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Goodrich

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Journal of the American Heart Association|April 26, 2022
Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease RegistryAnkeet S Bhatt, Anubodh S Varshney, Erica L Goodrich, et al.
JAMA Cardiology|July 20, 2022
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
JAMA Cardiology|August 7, 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, et al.
Circulation|November 1, 2017
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic AtherosclerosisIlaria Cavallari, David A Morrow, Mark A Creager, et al.
ESC Heart Failure|September 15, 2025
Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58Paul M Haller, Stephen D Wiviott, David D Berg, et al.
The New England Journal of Medicine|April 8, 2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular RiskBrian A Bergmark, Nicholas A Marston, Thomas A Prohaska, et al.
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Diabetes Care|January 11, 2022
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Blood|May 29, 2026
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71Andre Maurice Small, Siddharth M Patel, Robert P Giugliano, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Journal of the American Heart Association|April 26, 2022
Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease RegistryAnkeet S Bhatt, Anubodh S Varshney, Erica L Goodrich, et al.
JAMA Cardiology|July 20, 2022
Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
JAMA Cardiology|August 7, 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, et al.
Circulation|November 1, 2017
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic AtherosclerosisIlaria Cavallari, David A Morrow, Mark A Creager, et al.
ESC Heart Failure|September 15, 2025
Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58Paul M Haller, Stephen D Wiviott, David D Berg, et al.
The New England Journal of Medicine|April 8, 2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular RiskBrian A Bergmark, Nicholas A Marston, Thomas A Prohaska, et al.
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Diabetes Care|January 11, 2022
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Blood|May 29, 2026
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71Andre Maurice Small, Siddharth M Patel, Robert P Giugliano, et al.
Pageof 12